ECTRIMS 2019: Cladribine as treatment of multiple sclerosis, real world experience

Elisabeth Gulowsen Celius | ECTRIMS 2019 | Septttember 11, 2019

Föreläsare: Elisabeth Gulowsen Celius

In this MEDtalk Elisabeth Gulowsen Celius present data from a real-world population of patients with previous treatments cladribine. Cladribine is a synthetic purine nucleoside analogue administered orally as two five day treatment cycles week 1 and 5 and repeated one year later. Cladribine gained market access in Norway in May 2018.